AK112 in Advanced Non-Small Cell Lung Cancer

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

398

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

January 29, 2024

Study Completion Date

December 31, 2025

Conditions

Advanced Non-small-cell Lung Cancer

Interventions

DRUG

AK112

Subjects receive AK112 intravenously.

DRUG

Pembrolizumab

Subjects receive Pembrolizumab intravenously.

Trial Locations (1)

Shanghai Pulmonary Hospital, Shanghai